Border

Happenings from ASCO 2026

Border

ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and RAS-targeted therapies to the growing influence of Chinese biotech on the global stage, this year’s meeting showcased the evolving future of cancer care. Listen to the recap: https://www.fiercepharma.com/pharma/behind-headlines-asco-2026

Did you find this helpful? Share with your network!

More Tips From The Bandish Group

Border Line

Happenings from ASCO 2026

ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and…

Supply Chain Challenges in Clinical Development

Mehran Bhatti, CEng, CPSM, ATMP, and Biotech Supply Chain and External Manufacturing Specialist at Accenture, takes an interesting look at…

Scroll to Top